India's Cancer Drug Margin Cap Takes Effect Monday: 1,031 Formulations Cut, Steepest Drop 96.45%

Since the National Pharmaceutical Pricing Authority (NPPA) issued its Oct. 17 order capping trade margins on 137 anti-cancer drugs, the numbers behind it have firmed up. The new prices take effect Monday, Nov. 9.

The Ministry of Chemicals and Fertilisers says 76 pharmaceutical companies have so far filed revised maximum retail prices (MRPs) for 1,225 formulations covering 121 drugs. Prices fell on 1,031 of those formulations. Roughly 600 brands cut their MRP by more than 50%. The steepest drop is 96.45%.

What the order does

The NPPA capped the trade margin at 30% of MRP, excluding GST. That margin is the gap between what a company charges the distribution chain and what the patient pays at the counter. Distributors and chemists keep it.

These 137 drugs are "non-scheduled," meaning they sit outside the government's formal price-control list. The NPPA got around that by invoking Paragraph 19 of the Drugs (Prices Control) Order, 2013.

The ministry says the order followed recommendations made Oct. 17 by an expert committee constituted under the Directorate General of Health Services. The Supreme Court had earlier flagged cases where the gap between supply price and MRP was especially wide.

The price cuts

The ministry's list shows wide variation. Some drugs fell more than 90%. Others fell by roughly half or less.

• RPG Life Sciences' Palbopro (palbociclib 125 mg), a breast cancer capsule: Rs 40,421.33 down to Rs 2,720.
• Arvincare Pharma's Abirone (abiraterone acetate 250 mg), a prostate cancer tablet: Rs 41,250 down to Rs 3,218.23.
• Zydus Lifesciences' Bryxta (bevacizumab 100 mg): Rs 25,995 down to Rs 3,318.
• Reliance Life Sciences' DenOsteoRel (denosumab 60 mg): Rs 24,955 down to Rs 6,240.
• Lupin's Lupiher 2 (pertuzumab 420 mg): Rs 83,520 down to Rs 37,358.30.
• Natco Pharma's Dasanat 20 (pack of 60 tablets): Rs 2,812.50 down to Rs 1,085.90.
• Hetero Healthcare's Fludanox (vial): Rs 14,235 down to Rs 2,432.

In a separate revised list, the NPPA put new MRPs on 543 anti-cancer brands. That list reflects company submissions through Oct. 27, 2026. The regulator says it will be updated as manufacturers file revised prices for non-scheduled anti-cancer drugs.

The covered drugs include immunotherapies such as pembrolizumab and durvalumab. They also include osimertinib for certain lung cancers, bevacizumab, denosumab and pegfilgrastim.

The savings claim

The ministry's current estimate is Rs 3,502.31 crore a year in consumer savings. An earlier estimate, cited when the order was first announced, put the figure at about Rs 3,357.49 crore. The government projection has risen, but neither figure is a measured result. Nothing has been sold at the new prices yet.

The average MRP cut was initially described as 20% to 70%, with a handful of outliers far beyond that. The 96.45% figure is a ceiling, not a typical outcome.

The filings also show what the order has not fully reached so far. 137 drugs are covered by the order, but filings so far cover 121. The ministry says another 10 to 15 identified drugs not yet launched in India will fall under trade margin rationalisation when they are released.

Enforcement

Retailers, dealers and hospitals must prominently display the revised price lists on their premises and websites. State Drug Controllers are responsible for monitoring compliance.

Consumers can check prices on the NPPA portal or the Pharma Sahi Daam app. They can report violations through designated helplines, according to the ministry.

The order's practical effect depends on that last step. The NPPA has set the price cuts on paper, but selling at the new MRP falls to thousands of pharmacies and hospital counters across India.

What happens Monday

On Nov. 9, the revised MRPs become the legal ceiling for the covered drugs. The NPPA's list is still open: it will be updated as more of the remaining companies submit their prices. The first test will be whether chemists and hospitals actually charge those prices for the drugs on the list.